Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-three analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, twenty have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $175.55.

A number of research analysts have recently commented on SRPT shares. HC Wainwright reduced their target price on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating on the stock in a research report on Tuesday. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Evercore ISI lowered their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Finally, Raymond James restated an "outperform" rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th.

Sarepta Therapeutics Stock Up 1.5 %

Shares of NASDAQ:SRPT traded up $1.89 during mid-day trading on Friday, hitting $128.17. 619,477 shares of the company traded hands, compared to its average volume of 1,329,769. The firm has a market cap of $12.24 billion, a P/E ratio of 102.54 and a beta of 0.77. Sarepta Therapeutics has a 52-week low of $85.61 and a 52-week high of $173.25. The firm's 50 day simple moving average is $122.71 and its 200 day simple moving average is $131.32. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the company's stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 7.70% of the company's stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. Janus Henderson Group PLC raised its stake in Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Geode Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock valued at $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company's stock worth $94,148,000 after purchasing an additional 63,437 shares during the period. Finally, Thrivent Financial for Lutherans grew its position in Sarepta Therapeutics by 6.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company's stock valued at $101,858,000 after buying an additional 37,940 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.